None listed
Conditions
Interventions
Dietary Supplement : The main ingredient name is swallow's nest extract (22.22% of swallow's nest extract, 74.78% of maltodextrin, 1.50% of magnesium stearate, 1.50% of silicon dioxide). Usage and dos
Sponsors
Semyung University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Adult women aged 40 or more and less than 60 years of age 2) Subjects with wrinkles around the eyes and a global photo damage score of 2-6 3) Subjects who are not currently taking health functional foods or similar products for the purpose of improving skin health such as skin wrinkles, elasticity, moisturizing, and whitening 4) Subjects who have understood the purpose, contents, and possible adverse reactions of the study and have voluntarily signed a written consent
Exclusion criteria
Exclusion criteria: 1) Subjects with severe acute kidney disease, heart disease, liver disease, or other chronic disease that may affect the test results within the last 6 months 2) Subjects with a history of stroke or transient ischemic heart attack 3) Subjects with a history of malignancy or lung disease within 5 years of screening 4) Patients with uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg, measured after 10 minutes of rest) or uncontrolled diabetes patients (fasting blood sugar greater than 180 mg/dL) 5) Subjects with an important neurological or psychological history or currently suffering from diseases (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.) 6) Subjects with skin abnormalities such as spots, acne, tattoos, scars, erythema, capillary dilatation, and burn marks on the measurement site 7) Subjects who have used oral or applied retinoids/steroids within 6 months prior to the start of the test, or who have undergone skin peeling or skin wrinkle removal procedures 8) Subjects who have used functional cosmetics for wrinkle improvement (retinoids, AHA, etc.), highly moisturizing/elastic cosmetics, or skin care devices (LED mask, ion booster, etc.) within 2 weeks of screening 9) Subjects with eczematous skin diseases (eczema, atopic dermatitis, etc.) or infectious skin diseases 10) Subjects with allergic specific constitution (food, pollen, etc.) or hypersensitivity 11) Subjects with irritation or allergy to cosmetics, pharmaceuticals, health functional foods, and daily exposure to sunlight 12) Subjects with a history of hypersensitivity (allergy) to swallow's nest extract 13) Pregnant women, lactating women, those planning to become pregnant, and those taking contraceptives or female hormones 14) Subjects receiving other prohibited treatment (insulin, antidepressant, antiserotonin, barbiturate, antipsychotic, drug with potential for abuse, absorption inhibitor, appetite suppressant, etc.) 15) Subjects who have used steroid-containing skin external agents for 2 weeks or more for the treatment of skin diseases 16) Subjects who have taken steroids (oral and injection), hormones, or drugs that affect absorption, distribution, metabolism, and excretion of drugs within the past 3 months and drugs that may affect the skin 17) Subjects with abnormalities in the general opinion of the specialist as a result of blood and urine tests (AST, ALT, ALP, ?-GT, and total bilirubin levels are more than 3 times the upper limit reference value (UNL), and serum creatinine levels are the upper limit reference value (UNL)) more than twice the 18) Subjects within 3 months of participating in the same trial 19) Other subjects who are considered unsuitable for the study at the discretion of the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of skin wrinkle using SV700 after 12 weeks compared to baseline;Change in skin elasticity using cutometer after 12 weeks from base;Change of skin moisture using Corneometer after 12 weeks from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in skin wrinkles using SV700 at 4 and 8 weeks from baseline;Changes in skin elasticity using a cutometer at 4 and 8 weeks from baseline;Changes in skin moisture using Corneometer at 4 and 8 weeks from baseline;Changes in the amount of transdermal water loss using Tewameter at 4 weeks, 8 weeks, and 12 weeks from the baseline;Changes in melanin index and erythema index using Mexameter at 4, 8, and 12 weeks from baseline;Changes in the visual evaluation of skin wrinkles by experts at 4, 8, and 12 weeks from the baseline | — |
Countries
Korea, Republic of
Contacts
Public ContactKim hyungmook
Semyung University
Outcome results
None listed